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Background: Reduction of the stigma of mental illness is an international priority; arts- and contact-based approaches
represent a promising mode of intervention. This project was designed to explore the impact of a one-woman theatrical
performance on attitudes towards bipolar disorder (BD) on people with BD and healthcare providers.
Methods: A playwright and actress who lives with BD developed a stage performance - ‘That’s Just Crazy Talk’ - targeting
stigmatizing attitudes towards BD. Prospective, longitudinal and sequential mixed methods were used to assess the
impact of the performance on people with BD (n = 80) and healthcare providers (n = 84). Qualitative interviews were
conducted with 33 participants (14 people with BD and 19 healthcare providers).
Results and Discussion: Quantitatively, healthcare providers showed significantly improved attitudes immediately
post-performance, but this change was not maintained over time; people with BD showed little quantitative change.
Qualitatively, both people with BD and BD healthcare providers showed enduring and broadly positive changes. A
theatrical presentation designed to reduce stigma produced immediate impact on healthcare providers quantitatively
and significant qualitative impact on people with BD and healthcare providers. Additionally, the utility of using
mixed-method approaches in mental health research was demonstrated.
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Mental health is determined by myriad factors, not
simply the absence of specific symptoms or disorders.
For people living with psychiatric conditions, stigma can
play a pernicious role. Stigma is a dynamic, multifaceted
social process in which people are devalued and discredited
on the basis of a stereotyped social status or personal
characteristic (Weiss et al. 2006). It has been consistently
implicated as a key contributor to poor outcomes for
many people who live with stigmatized health conditions,
such as psychiatric conditions (Livingston and Boyd
2010). Although a large body of literature has accrued in
relation to stigma and mental illnesses broadly (for review,
see Hinshaw and Stier 2008; Schomerus et al. 2012), the
literature on the specific relationship between stigma and
bipolar disorder (BD) is comparatively lean. Nevertheless,
this body of evidence does indicate that stigma experiences
and perceptions are a common occurrence for people with* Correspondence: erin.michalak@ubc.ca
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in any medium, provided the original work is pBD and their families and that stigma can have severe
repercussions (Michalak et al. 2011). For example, higher
perceptions of stigma are associated with increased
symptom severity and reduced functioning (Aydemir
and Akkaya 2011; Cerit et al. 2011; Vázquez et al. 2011)
and greater concealment, social withdrawal and social
anxiety among people with BD (Aydemis and Akkaya
2011; Michalak et al. 2006; Michalak et al. 2007).
From a treatment perspective, people with higher
self-stigma are less inclined to seek professional help
(Yap et al. 2011), less likely to adhere to treatment when
they do seek help (Fung et al. 2008; Tsang et al. 2010) and
more likely to experience poorer therapeutic alliance with
healthcare providers (Kondrat and Early 2010). Mental
healthcare providers have been found to have relatively
positive attitudes towards people with mental illness but
are not free from stigmatizing attitudes and expectations,
particularly with respect to the social acceptance of people
with mental illness. Given the complex interrelations
between stigma, symptoms, treatment seeking, and disorder
management and treatment, modifying stigma may have
major therapeutic benefit.s an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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more likely to be effective when tailored to the clinical
profile of specific conditions (Hinshaw and Stier 2008;
Sartorius and Schulze 2005), yet few stigma interventions
targeted towards BD have been developed. Emerging
evidence also indicates that an effective multifaceted
strategy to prevent and reduce mental illness stigma would
include creative arts and contact-based approaches (where
contact approaches refer to anti-stigma interventions that
rely on planned interactions between people with mental
illness and the public (Corrigan 2012)). Theatre holds
particular potential as one example of a creative arts-based
approach, employing the tools of ethnography and artistry
to convey complex messages with social and personal
meaning. It also has entertainment value, which may facili-
tate dissemination. To date, the impact of theatre-based
interventions have been applied in a variety of physical
health conditions, such as brain injury and end-of-life care
(Rossiter et al. 2008; Lorenz et al. 2004). Theatre has also
been specifically employed to fight mental illness
stigma. For example, the performance arts have been
shown to help reduce stigma toward mental illness
among teenagers and young adults (Faigin and Stein 2008;
Roberts et al. 2007; Twardzicki 2008). One study evaluated
a mental health festival, which brought tougher multiple
arts-based interventions, and found modest positive
impacts (Quinn et al. 2011). Theatrical interventions rep-
resent an example of narrative medicine (Greenhalgh and
Hurwitz 1999) and a specific knowledge translation (KT)
strategy (Eakin and Endicott 2006).
Here, we report on a study that investigated the effects
of a theatrical performance that told a personal story
about struggling with and managing stigma from the
perspective of a woman living with BD. Our primary
objective was to examine the effects of this intervention
on the attitudes of people who live with the condition and
healthcare providers.
Methods
Study design and participants
The study adopted a prospective, longitudinal, sequential
mixed methods design in order to assess the impact of the
performance on stigma using qualitative and quantitative
approaches. Study participants included people with lived
experience of BD and BD healthcare service providers
in two large metropolitan Canadian cites: Vancouver
and Toronto. Healthcare provider participants were aged
19 years or older, involved in the provision of care (direct
or indirect) to people with BD and able to communicate
in English. Participants in the people with BD group were
aged 19 years or older, had a self-reported diagnosis of
BD, and were able to communicate in English.
Ethical approval for the study was provided by the
University of British Columbia and the University ofToronto, and written informed consent was obtained from
all the participants. The participants were remunerated
in the form of a $10 coffee card for participating in the
quantitative evaluation, $30 for the qualitative evaluation
and all participants received a DVD recording of the
performance at the end of the study.
Recruitment and study procedure
The study participants were recruited with multiple
methods including our CREST.BD research network’s
face-to-face, on-line and social media communications
(e.g. public education events, email newsletter announce-
ments, postings on the team’s website, Facebook and
Twitter accounts). Study advertisements were dis-
seminated through a wide range of consumer-focused
(e.g. Mood Disorders Association of British Columbia, Mood
Disorders Association of Ontario and Canadian Mental
Health Association) and healthcare provider-focused
associations (e.g. Canadian Psychiatric Association).
Additional email announcements were sent through
hospital and university email communications in Vancouver
and Toronto.
People who were interested in attending a performance
were asked to register by telephone or on line. At the
point of registration, they were asked to self-select as a
person with BD or a BD healthcare provider. Registration
preference was given to research participants, but general
audience members not involved in the research process
were welcome at all performances, space permitting. In
the week preceding the performance, potential research
participants were emailed a consent form, background
information and sociodemographic form, and two
standardized stigma measures (described below). Research
participants, therefore, completed the baseline (T1) stigma
measures either in the 7 days leading up to the performance
or on the actual day of the performance. The measures
were re-administered immediately after the performance
(T2), but prior to the question and answer period
with the actress. In addition to the stigma measures,
the T2 questionnaire included customized questions
asking participants to evaluate various aspects of the
performance.
Research participants who provided consent to re-contact
were also requested (by email and telephone, up four times
before being classified as a non-responder) to completed
the stigma scales 3 to 4 months after the performance (T3).
Drawing on the strengths of a sequential mixed methods
design, the qualitative methods were embedded within
the overall design, and the findings of the quantitative
analyses informed the development of the qualitative
interviews (Creswell and Clark 2011; Klassen et. al 2012).
The participants were purposively selected for a 3-month
interview based on the nature of their pre-post change
on the quantitative stigma measures, with participants
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demonstrated a statistically reliable reductions or increase
in stigma on at least one of the measures and participants
who experienced no reliable change. Interviews occurred
at 3 months in order to allow for the assessment of
whether any post-performance changes were maintained
over the short to medium term and to allow time for the
detection of any behavioural change.
Semi-structured interviews were conducted to elicit an
in-depth conversation of the participants’ perceptions of
the impact of the play in order to complement the
quantitative findings. The interviews were conducted
by telephone. Nineteen or 56% were performed by EM, an
experienced qualitative researcher, and the remainder by
one of two peer researchers (a counselling psychology
student or a therapist, both of whom live with BD), as per
our community-based participatory research (CBPR)
approach. All interviews were digitally recorded and
transcribed verbatim. Thematic analysis was used to
identify themes across participant interviews (Braun and
Clark 2006). Three members of the research team analyzed
the first seven transcripts together to create a coding
framework. Subsequent transcripts were co-analyzed and
discussed in relation to the emerging coding framework
and themes identified. Once analyzed, the quantitative
findings were compared with the themes that emerged
from the qualitative analysis. These interpretive processes
provided a context for the trends found in the quantitative
analyses: the qualitative findings helped explain in
quantitative findings (Creswell and Clark 2011; Klassen
et al. 2012).
Intervention
This study represents a CBPR project in which academic
researchers worked closely with an established actress
and playwright who lives with BD type I (Victoria
Maxwell, Crazy for Life Co., Sechelt, British Columbia,
Canada) and developed a one-woman stage play specifically
targeted towards BD stigma. VM and the research team
worked closely during the early stages of developing the
performance, for example, an early draft of the play was
reviewed by the investigators to confirm that its themes
mapped onto stigma issues identified in the literature.
Specifically, the literature identifies internalized stigma
experienced by the individual with BD and difficult
encounters in workplace, relationship, and general settings
(Michalak et al. 2011; Vázquez et al. 2011); all of these
were captured in the play. After these initial discussions,
VM was given full creative freedom.
In terms of producing the play, the services of a
dramaturge who helped edit and shape the narrative arc
of the storyline was engaged for the writing process. A
director was hired for the rehearsal process prior to the
premiere staging of the show. The rehearsal period was6 weeks of 4-h meetings, 3 to 4 times each week. The
research team was not present for any of the rehearsals.
The final version of the play that premiered on stage
was a result of an artistic process that came from the
playwright’s personal experiences, unhampered by ideas
or themes artificially imposed by the academic team. It
should be noted that VM was not involved in carrying
out the research or analyzing the data. The resulting
performance - ‘That’s Just Crazy Talk’ - consisted of an
approximately 50-min performance, followed by an
approximately 30-min question and answer period
with the actress. The audiences comprised a mix of
people with BD and BD healthcare providers and general
audience members. The team was prepared to deal
with any emotional decompensation of attendees at
the performances, but no such crisis emerged.
In the performance, the dramatic narrative conveys
the corollaries of decades of personal and familial mental
illness, translating the narrator’s experiences of external
and internal stigma into a vivid, often humorous and
sometimes troubled, portrait of life lived with BD. Two
performances were given in Vancouver and one in
Toronto. All occurred in mid-sized, accessible and central
downtown theatre venues and played to near-capacity
houses.
Measures
Day’s Mental Illness Stigma Scale
This self-report measure of stigmatizing attitudes toward
mental illness consists of 28 items and contains seven
subscales: interpersonal anxiety, relationship disruption,
hygiene, visibility, treatability, professional efficacy and
recovery (Day et al. 2007). In this study, we substituted
the word ‘mental illness’ with ‘bipolar disorder’. For each
item, the participants are asked to rate their level of
agreement using a seven-point scale ranging from
completely disagree (1) to completely agree (7). We
also modified the scoring procedures by reverse-coding
five items (1, 7, 9, 23 and 28) to ensure that higher scores
were consistently indicative of greater levels of stigma
across all items and subscales. The participants in both
the people with BD and healthcare provider groups
completed the Day’s Mental Illness Stigma Scale.
Mental Illness: Clinicians’ Attitudes Scale Version 4
This is a self-report measure of healthcare profes-
sionals’ attitudes toward people with mental illness
(Kassam et al. 2010). The Mental Illness: Clinicians’
Attitudes Scale Version 4 (MICA-4) poses 16 statements
for which the participants are asked to rate their level of
agreement using an anchored six-point scale ranging from
strongly agree (1) to strongly disagree (6). Reverse-coding
was performed on ten items. The scores for each item were
summed to produce a single overall score. Higher MICA-4
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attitudes toward mental illness. Only participants in
the healthcare provider group completed the MICA-4.Internalized Stigma of Mental Illness scale
The Internalized Stigma of Mental Illness (ISMI) scale is
a self-report questionnaire that is designed to measure
the internalized, subjective experiences of stigma for
people living with mental illness (Ritsher 2003). The ISMI
consists of 29 items and contains five subscales: alienation,
stereotype endorsement, discrimination experience, social
withdrawal and stigma resistance. For each item, the
participants are asked to rate their level of agreement
using an anchored four-point scale that ranges from
strongly disagree (1) to strongly agree (4). Items in
the stigma resistance substance are reverse scored.
The subscale scores and a total score are calculated
by averaging the respondents’ ratings, with higher
scores indicating higher levels of self-stigma. Only the
participants in the people with BD group completed
the ISMI scale.Performance evaluation
The participants were asked a range of questions pertaining
to their perceptions of the event such as whether they
learnt something new during the performance, the teaching
effectiveness of the performer, whether the performance
had an emotional impact on them, whether they thought it
could change public/mental healthcare providers’/their own
acceptance of BD and overall satisfaction with the event.
The evaluation forms were similar for people with BD and
BD healthcare providers.Sample size and power
Power analysis with G*Power 3 indicated that a minimum
of 71 participants in each group was needed for a power
of 80% (p < 0.05, one-tailed, effect size = 0.30). Eighty-four
people with BD and 87 healthcare providers consented to
participate in the study. Data from four people with BD
and three healthcare providers were omitted from the
analysis because of missing data. The analyses were
therefore performed on data from 80 people with BD
and 84 healthcare providers. Three research participants
met the study inclusion criteria as both a BD healthcare
provider and a person with BD; for analytic purposes,
these participants were included in the ‘people with
BD’ group for analysis. At T3, 37 (46.3%) people with
BD and 43 (51.2%) healthcare providers were retained.
Bivariate comparisons of participants who were or were
not retained at T3 revealed no significant differences
(p > 0.05) in gender, mean age and total mean scores
on the DMISS, MICA and ISMI at T1.Data analysis
Quantitative data were analyzed using SPSS version 14
(for Windows, IBM Corporation, Armonk, NY, USA).
Effect sizes were calculated using G*Power 3. Paired
sample t tests were conducted in order to compare T1
and T2 subscale and total scores of the dependent
measures among people with BD and healthcare providers.
Pairwise deletion was used to remove specific missing
values from the analysis. To assess the effect of time (T1,
T2 and T3) on average total stigma scores, we performed a
repeated measures MANOVA, with ‘time’ specified as the
within-subjects factor. Only total scores were used, rather
than subscale scores, for analyzing the three waves of data
in order to reduce the number of comparisons made given
the small sample size at T3. The total scores from cases
with too many missing items (e.g. more than three) were
removed from the analyses. Mauchly’s Test of Sphericity
was significant on the DMISS for both groups in addition
to the ISMI for people with BD, indicating that sphericity
cannot be assumed. In these instances, we relied on the
Greenhouse-Geisser correction procedure.Results
Participants
A total of 164 participants (80 people with BD and 84
healthcare providers) were included in the quantitative
analyses. Overall, the majority of the total sample were
female (n = 127, 77.9%), and the average age was 41 years
(SD = 12.6, range = 21 to 74 years).
For the people with BD sample specifically, 71% were fe-
male, 26% male and 2% otherwise gendered with a mean
age of 42.4 years (SD = 12.2, range = 21 to 71 years). In com-
parison, in the healthcare provider group specifically, 84%
were female and 16% male with a mean age of 40.2 years
(SD= 12.9, range = 23 to 74 years). The majority of the
people with BD sample described themselves as white/
Caucasian (n = 63 or 83%) with the second most commonly
endorsed racial identity being Asian (n = 7 or 8.2%). On
average, people with BD (n = 79) reported living with the
condition for 10.1 (SD = 9.1) years. For the healthcare pro-
vider group, 16 (19.3%) of the sample were nurses, 8 (9.6%)
psychologists, 6 (7.2%) psychiatrists, 6 (7.2%) occupational
therapists, 5(6.0) psychology trainees, 4 (4.8) social workers
and 38 (45%) coming from ‘other’ healthcare disciplines.
The average years of healthcare practice across all disci-
plines (n = 71) was 12.1 years (SD = 11.9). Three quarters
of the healthcare provider sample (75.9%) had not seen a
different performance by Victoria Maxwell, whereas 84%
of the people with BD sample had not. No significant
differences were observed in any of these descriptive
variables between groups, or in distribution of healthcare
provider versus people with BD participants across data
collection sites (Vancouver vs. Toronto). In total, 195
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three performances.
A total of 33 participants (9 males and 24 females)
were included in the qualitative phase. The sample
included 14 people with self-reported BD (BD type I = 8,
BD type II = 5; NOS = 1) and 19 healthcare providers
(2 psychiatrists, 4 nurses, 5 psychologists, 2 occupational
therapists and 6 others). Of this sample, ten participants
demonstrated significant change on the quantitative
measures, demonstrating a reduction in stigma; 18 partici-
pants showed no change, and a further 5 demonstrated
change for the worse.
Quantitative results
General evaluation
In order to understand the ‘face validity’ of the performance,
questions on the play and its potential to alter stigma were
asked: 98% of the participants described the show as ‘good’
or ‘excellent’ with positive feedback across people with BD,
healthcare providers and general audience members. The
performance was judged to have the potential to affect
stigma, as 67% people with BD and 85% of healthcare
providers thought the play could ‘change public acceptance
of BD’ (see Table 1). With the common DMISS, at baseline,
healthcare providers had significantly lower total average
scores than people with BD, t (162) = −4.90, p < 0.001,
indicating that they held more positive attitudes toward
people with BD (see Table 2).
Tables 3 and 4 summarize the average scores on the
stigma measures for healthcare providers and people
with BD at T1 and T2. At T2, immediately following the
intervention, healthcare providers demonstrated significant
change across the five DMISS subscales and the total
score, indicating improvements in attitudes toward BD. In
comparison, the average scores for people with BD
significantly changed on only one DMISS subscale
(relationship disruption). The average DMISS total score
for 42 healthcare providers who were interviewed at three
time points was 2.29 (SD = 0.65) at T1, 2.07 (SD = 0.60) at
T2, and 2.19 (SD = 0.60) at T3. A repeated measures
MANOVA indicated that the time effect was significant
for the DMISS total score, F (1.45, 59.33) = 5.28, p = 0.015;
however, within-subjects contrasts revealed that the time
trend was quadratic. Therefore, stigmatizing attitudes
decreased immediately following the intervention but then
increased to almost baseline levels at 3-month follow-up
in providers. Average DMISS total scores for 36 people
with BD who were interviewed at three time points were
2.73 (SD = 0.79) at T1, 2.70 (SD = 0.92) at T2, and 2.58
(SD = 0.86) at T3; the time effect was not significant,
F (1.66, 57.95) = 1.72, p = 0.192.
The results from the MICA-4 and ISMI revealed a
different pattern. For healthcare providers, no significant
change was seen between T1 and T2 on the MICA-4.Average MICA-4 total score for 40 healthcare providers
who were interviewed at three time points was 29.40
(SD = 5.82) at T1, 27.58 (SD = 5.83) at T2, and 29.85
(SD = 6.47) at T3. A repeated measures MANOVA
indicated a significant time effect for the MICA-4 total,
F (2, 78) = 4.31, p = 0.017; however, within-subjects contrasts
revealed that the time trend was quadratic. Therefore,
stigmatizing attitudes decreased immediately following
the intervention but then increased to baseline levels
at 3-month follow-up. For individuals with BD, only
one subscale of the ISMI (alienation) showed change
from T1 to T2. The ISMI total scores remained stable
between T1 and T2, t (74) = 1.00, p = 0.319. The average
ISMI total scores for 34 people with BD who were
interviewed at three time points were 2.04 (SD = 0.50)
at T1, 2.02 (SD = 0.55) at T2, and 2.84 (SD = 0.36) at T3.
A repeated measures MANOVA indicated a significant
linear time effect, F (1.13, 37.20) = 30.24, p < 0.001.
Therefore, stigmatizing attitudes were significantly elevated
at 3-month follow-up for people with BD.
Qualitative results
By and large, all individuals participating in the qualitative
interviews indicted that the performance had a positive
impact on their understandings of BD. In particular, they
valued the unique learning opportunity (e.g. accessible
presentation style) and the emotional impact of the
performance. Specifically, they described how the perform-
ance informed them about the following: (1) the complexity
and heterogeneity of BD experiences, (2) the possibility and
opportunity for recovery (e.g. hope) and, relatedly, (3) a
demystification of the experience of BD (see Table 5). The
participants who had demonstrated significant positive
change quantitatively typically described that this change
occurred as a result of increased empathy, hope, and/or
openness (for themselves and/or for others living with BD)
(see Table 6). The subset of individuals interviewed who did
not demonstrate significant change on the quantitative mea-
sures indicated that the performance had held meaningful
impact for them; they described their experience of That’s
Just Crazy Talk as a positive reminder and/or a confirmation
of their views and beliefs regarding BD (see Table 7).
Discussion
Stigma is an important determinant of health and quality of
life in people with mental illness (Hinshaw and Stier 2008;
Schomerus et al. 2012) and has such has been prioritized as
a key target by national bodies such as the Mental Health
Commission of Canada (Kirby 2008). Bipolar disorder
is certainly not immune to stigma; our own program
of research has demonstrated that stigma is a major
concern for people with BD and their family members
(Michalak et al. 2011; Suto et al. 2012), as has that of other
research groups (Mileva et al. 2013). Given its pervasiveness
Table 1 Evaluation measures
Providers (n = 84) People w/ BD (n = 80) Test
N Valid% or mean N Valid% or mean
Participant learned something new
Poor (1) 0 0 2 2.7
Fair (2) 0 0 2 2.7
Neutral (3) 16 20.3 26 35.1
Good (4) 42 53.2 26 35.1
Excellent (5) 21 26.7 18 24.3
M (SD) 79 4.06 (0.69) 74 3.76 (0.95) t (132) = 2.27, p = 0.024a
Teaching effectiveness of presenter
Poor (1) 0 0 0 0
Fair (2) 1 1.3 0 0
Neutral (3) 0 0 5 6.8
Good (4) 11 13.9 17 23.0
Excellent (5) 67 84.8 52 70.3
M (SD) 79 4.82 (0.47) 74 4.64 (0.61) t (138) = 2.12, p = 0.036a
Emotional impact on participant
Poor (1) 0 0 0 0
Fair (2) 0 0 3 4.2
Neutral (3) 7 9.0 3 4.2
Good (4) 20 25.6 28 38.9
Excellent (5) 51 65.4 38 52.8
M (SD) 78 4.56 (0.66) 72 4.40 (0.76) t (148) = 1.39, p = 0.166
Length of event
Poor (1) 0 0 1 1.4
Fair (2) 1 1.3 1 1.4
Neutral (3) 4 5.1 7 9.5
Good (4) 21 26.6 31 41.9
Excellent (5) 53 67.1 34 45.9
M (SD) 79 4.59 (0.65) 74 4.30 (0.81) t (151) = 2.52, p = 0.013
Overall satisfaction with content of event
Poor (1) 0 0 1 1.4
Fair (2) 0 0 1 1.4
Neutral (3) 0 0 4 5.4
Good (4) 20 25.3 19 25.7
Excellent (5) 79 74.7 49 66.2
M (SD) 79 4.75 (0.44) 74 4.54 (0.78) t (113) = 2.00, p = 0.048a
Overall rating of event
Poor (1) 0 0 1 1.4
Fair (2) 0 0 0 0
Neutral (3) 1 1.3 2 2.7
Good (4) 19 24.1 21 28.4
Excellent (5) 59 74.7 50 67.6
M (SD) 79 4.73 (0.47) 74 4.61 (0.68) t (129) = 1.33, p = 0.188a
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Table 1 Evaluation measures (Continued)
Could event change public acceptance of BD
No 0 0 1 1.9
Somewhat 11 13.8 10 18.5
Yes 69 86.3 43 79.6
Could event change non-MH providers’ acceptance of BD
No 0 0 na na
Somewhat 15 18.5 na na
Yes 65 81.3 na na
Could event change MH providers’ acceptance of BD
No 1 1.3 na na
Somewhat 16 20.0 na na
Yes 63 78.8 na na
Did event change participants’ acceptance of BD
No 24 30.4 20 37.0
Somewhat 18 22.8 14 25.9
Yes 37 46.8 20 37.0
na, not applicable. aUnequal variance t test.
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hope as a means of improving functioning, social support
and health and quality of life in people with BD. Much
work remains to be done, however, in terms of identifying
effective stigma reduction interventions in mental illness
broadly and in relation to BD specifically.
In this project, we utilized integrated KT methods to
develop a new one-woman theatrical performance
designed to ameliorate stigmatizing attitudes in two
target groups: people with BD and BD healthcare
providers. The intervention was deliberately designed to
include both groups at the same event as an additional
‘meta-message’ conveying the common humanity of both
and modelling that the groups could mix in a non-clinical
setting. At a broad level, we demonstrated high ‘face
validity’ for the intervention and observed high levelsTable 2 Comparison of baseline levels of stigma (DMISS) betw
Provider
N Mean SD N
Stigma (DMISS) (α = 0.89)
Treatability*** 84 1.74 0.76 8
Relationship disruption*** 84 2.38 0.99 8
Hygiene** 84 1.93 0.99 8
Anxiety 84 1.71 0.89 8
Visibility 84 3.40 0.84 8
Recovery*** 84 2.55 1.31 8
Professional efficacy 84 2.74 1.35 8
Total*** 84 2.26 0.63 8
*p < 0.05, two-tailed; **p < 0.01, two-tailed;***p < 0.001, two-tailed. aUnequal variancof satisfaction in both target groups, and the performance
was clearly perceived as both engaging and entertaining.
Our findings on the impact of the performance on
stigmatizing attitudes were more complex and need
to be unpacked in the context of the mixed methods
research approach we utilized. In terms of the quantitative
scores, in healthcare providers, we observed an immediate
significant impact on one quantitative measure, with
erosion of change over time. In people with BD, no
significant change was apparent in quantitative scores
with the exception of one subscale (the ISMI subscale that
assesses feelings of alienation); in fact, a few participants
appeared to get worse in terms of their stigma scores
immediate post-performance.
Had we only assessed change in stigma via quantitative
scales, these results would have suggested only a moderateeen healthcare providers and people with BD
Person with BD
Mean SD t df P
0 2.48 1.16 −4.82 135 0.000
0 3.22 1.23 −4.82a 152 0.000
0 2.44 1.30 −2.80a 148 0.006
0 1.97 0.99 −1.75 162 0.083
0 3.57 0.80 −1.36 162 0.176
0 3.59 1.87 −4.10a 141 0.000
0 3.18 1.52 −1.95 162 0.053
0 2.79 0.74 −4.90 162 0.000
e t test.
Table 3 Comparison of average stigma scores for healthcare providers (n = 84) before and after the performance
Stigma measures T1 T2 Repeated t test d
Mean SD Mean SD
DMISS
Treatability 1.74 0.76 1.52 0.54 t (83) = 2.94, p < 0.004 0.32
Relationship 2.38 0.99 2.06 0.94 t (83) = 4.35, p < 0.001 0.48
Hygiene 1.93 0.99 1.67 0.87 t (83) = 3.42, p = 0.001 0.37
Anxiety 1.72 0.89 1.60 0.82 t (83) = 2.14, p = 0.035 0.24
Visibility 3.40 0.84 3.40 0.83 t (83) = 0.01, p = 0.990 0.00
Recovery 2.55 1.31 2.20 1.38 t (83) = 2.44, p = 0.017 0.27
Professional efficacy 2.74 1.35 2.53 1.32 t (83) = 1.78, p = 0.079 0.20
Total 2.26 0.63 2.07 0.61 t (83) = 5.55, p < 0.001 0.58
MICA
Total sum 30.61 6.52 29.77 6.61 t (81) = 1.56, p = 0.123 0.17
DMISS, Day’s Mental Illness Stigma Scale; MICA, Mental Illness: Clinicians’ Attitudes Scale Version 4.
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effect on persons with BD. However, we purposefully
interviewed select participants several months after the
performance in order to further evaluate the potential
impact of the performance. A comparative and interpretive
analysis of both quantitative and qualitative findings
demonstrated that while quantitatively measured change
in stigmatizing attitudes eroded over time, individuals
participating in the qualitative interviews expressed
continued positive effects from the intervention. For
example, individuals participating in the qualitative




Treatability 2.48 1.16 2.33
Relationship 3.22 1.23 3.00
Hygiene 2.44 1.30 2.35
Anxiety 1.97 0.99 1.97
Visibility 3.57 0.80 3.68
Recovery 3.59 1.87 3.48
Professional efficacy 3.18 1.52 2.99
Total 2.79 0.74 2.71
ISMI
Alienation 2.35 0.70 2.23
Stereotype 1.55 0.45 1.56
Discrimination 2.20 0.63 2.24
Withdrawal 2.04 0.68 2.05
Resistance 2.02 0.61 1.93
Total 2.01 0.49 1.98
DMISS, Day’s Mental Illness Stigma Scale; ISMI, Internalized Stigma of Mental Illnessattending the play (e.g., understanding about the spectrum
of BD and the heterogeneity of experiences). In
addition, both individuals with BD and healthcare providers
expressed that the performance resonated with their
experiences and had made them ‘more hopeful’, ‘more
empathetic’ and ‘more open’.
Notably, the qualitative findings added important
insights around the lack of quantitative change observed
in some participants. When probed, these participants
described what they interpreted as a floor effect, specific-
ally, that they felt they already had a lot of empathy for
individuals living with BD and a lot of knowledge aboutBD (n = 80) before and after the performance
T2 Repeated t test (two-tailed) d
SD
1.19 t (79) = 1.61, p =0.111 0.17
1.22 t (79) = 2.42, p = 0.018 0.27
1.36 t (79) = 0.98, p = 0.332 0.11
0.99 t (79) = 0.03, p = 0.978 0.00
0.85 t (79) = −1.10, p = 0.277 0.14
1.95 t (79) = 0.69, p = 0.495 0.07
1.53 t (79) = 1.39, p = 0.170 0.15
0.80 t (79) = 1.76, p = 0.083 0.19
0.77 t (77) = 2.61, p = 0.011 0.31
0.45 t (76) = −0.48, p = 0.635 0.04
0.72 t (74) = −0.61, p = 0.542 0.08
0.75 t (78) = −0.32, p = 0.751 0.02
0.58 t (76) = 1.14, p = 0.259 0.14
0.55 t (74) = 1.00, p = 0.319 0.13
scale.
Table 5 Qualitative findings across participants
Qualitative finding Participant quotes
Emotional impact of That’s Just Crazy Talk It was downright entertaining and moving. 03-HP007
Authentic Knowing that she’s an actress, but knowing that she actually lived it (…)
had an impact. 03-HP009
Reliable It just was kind of like reading your own journal but through someone else’s
eyes. 02-HP006 (HP&CM)
Courageous The key factors for me would be that she was really fearless about telling her
story. 02-CM006
That’s Just Crazy Talk as a unique learning opportunity I thought it was very helpful just to hear the experience from a person’s
perspective who actually was struggling with the disorder. 02-HP010
The complexity and heterogeneity of BD experiences More specifically that, I’m seeing that there’s more levels of disorder than what
I’ve experienced. 01-CM029
The possibility and opportunity for recovery (e.g. hope) That’s powerful, because it gives you an image that people can get better, you
know. This is where she was at, and this is how she is now. 02-HP027
A demystification of the experiences of BD I think it just reminded me that they’re just like you and me. They’re just a person
who has a story. 02-HP006
CM = person with BD; HP = healthcare provider.
Michalak et al. International Journal of Bipolar Disorders 2014, 2:1 Page 9 of 12
http://www.journalbipolardisorders.com/content/2/1/1the condition. Interestingly, for these individuals, the
notion of ‘no change’ did not equate to ‘no impact’. In
fact, these participants described an impact where the play
acted as a reminder and confirmation of their beliefs and
attitudes, for example, participants described that the play
reminded them of the importance of being empathetic
and compassionate and of valuing the subjective nature of
human experience. Indeed, arts-based approaches may
represent a particularly effective method for reaffirming
empathy and raising awareness about how people subject-
ively experience illness and health challenges.
Why did the quantitative change observed in the health-
care provider group erode over time? Other research
studies have similarly sown relatively modest impacts
from short-term interventions (e.g. Quinn et al. 2011;
Faigin and Stein 2008); stigmatizing attitudes can be
obstinate, consequently current recommendations call for
continuous, long-term stigma-reduction campaigns rather
than single, short-term interventions (Stuart et al. 2012).
Extensive, long-term stigma-reduction campaigns willTable 6 Subset of participants who demonstrated positive ch
Qualitative finding Participant quotes
Increased empathy Going from less infor
my compassion. 01-C
1. Increased hope Hope for recovery. (…
what they’ve lived an
It made me feel hope
that were watching it
2. Increased openness I’m probably more vo
I saw it. 01-HP024
It made me, you know
tell people I have bip
CM = person with lived experience of BD; HP = healthcare provider.require substantial toolkits of interventions to maintain
novelty and momentum. While each component of
such toolkit may have a modest impact, multiple
interventions may each reinforce the message of the
other, together accomplishing broad-based, sustainable
change (Rossiter et al. 2008). In support of this
approach, we filmed one of the live performances of
That’s Just Crazy Talk and produced a DVD version
of the show, which was also demonstrated to have a
positive impact on stigmatizing attitudes in healthcare
providers (Hawke et al. 2013).
Is the impact of this performance specifically effective
for people with BD or specialist BD healthcare providers?
On the one hand, stigma is a social process that
likely has universal features and consequences regardless
of the specific disorder or social status. We focused
on assessing the impact of That’s Just Crazy Talk on
people with BD and healthcare providers. Although
general audience members responded positively to the
performance, we did not assess its impact on stigmatizingange (quantitatively)
mation to after the play having more information has (…) opened up
M029
) Anyone else that I meet that suffers from this and that is honest about
d how they’ve lived, and can share that – that gives me hope. 03-CM017
ful for the reduction in stigma. It made me feel hopeful for other people
that would be inspired by her. 01-HP43
cal about how it, about talking about mental illness than I was before
, more comfortable and maybe, made me maybe a little more able to
olar disorder. 02-CM006
Table 7 Subset of participants who did not demonstrate change (quantitatively)
Qualitative finding Participant quotes
Meaningful impact: a positive reminder and/or confirmation
of their views and beliefs regarding BD
I think it did affirm the importance of being able to see things from
the patient’s perspective and always keeping that in mind. 02-HP010
HP = healthcare provider.
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dence that different illnesses can be associated with differ-
ent stereotypes (Crisp et al. 2000; Angermeyer et al. 2003;
Durand-Zaleski 2012), leading to the suggestion that that
anti-stigma initiatives will be more successful if they target
a specific condition rather than mental illness broadly
(Reavley and Jorm 2011).
Design considerations
Several potential limitations to this research require
consideration. The first grouping of limitations relates
to our study sample. No confirmation of diagnosis of BD
was made in the study; it is probable that a proportion of
the lived experience sample may not have met standard
psychiatric diagnostic criteria for BD. Further, the sample
of participants with BD and healthcare providers was
self-selected; it cannot be assumed that they represent
the average person with BD or the average healthcare
provider, and our attrition rate by T3 was substantial.
Finally, no assessment of mood state was made in the
participants with BD at the time of the performance.
The second grouping of limitations relates to study
design. Our design did not include a non-intervention
comparison group. There should also be consideration
as to the timing of our assessment points. We purposefully
conducted the T2 assessment point immediately after the
performance but prior to the Q&A session, thinking that
we wanted to assess the impact of the play specifically
and that the Q&A session would not be standardized in
delivery across different performances. However, this
decision meant that we did not capture the impact of
the post-performance discussions quantitatively, potentially
a lost opportunity given that several participants
mentioned in the qualitative interviews that this part
of the intervention was particularly meaningful or
evocative. A significant limitation in our study design
occurs in that the ‘intervention’ being evaluated at
the T2 assessment point does not include the Q&A
period. However, for T3, the Q&A is included in the
‘intervention’ as participants were exposed to this between
T2 and T3. The factors make it difficult to ascertain
whether the impact was the result of the performance
itself or the Q&A, although we will be addressing this
point in the full report on the qualitative findings
from the study.
There exists a growing body of research about using
live performances to illustrate patients’ perspectives onillness for mixed audiences of healthcare providers and
patients (e.g. Shapiro and Hunt 2003). Our research and
qualitative questions were not, however, designed to cap-
ture any impact (positive or negative) of targeting both
people with BD and healthcare providers simultan-
eously. Relatedly, perhaps the T2 assessment point
was not ideally timed in terms of allowing participants
adequate time to process what was, for some, emotionally
moving material. With hindsight, it would have been in-
teresting to assess the impact of the performance a day or
two after the show.
Our third grouping of limitations relates to our selected
assessment scales. A growing number of scales designed
to measure stigma have emerged; however, their ability to
detect change has not been fully tested. This is certainly
true of the measures used in the current study. Moreover,
the scales used in this study are explicit measures of
attitudes and beliefs (i.e. conscious and controllable),
which are prone to social desirability bias. The possibility
of social desirability bias when completing stigma assess-
ments should also be a consideration in research of this
nature, perhaps by incorporating implicit measures of
stigma, although the likelihood of this occurring would
have been lessened as the questionnaires were completed
anonymously.
Conclusions
Theatrical traditions clearly hold the potential to impact
audience members, both at affective and cognitive levels,
and to foster insight and deepened understanding. In
recognition of this, there is a growing body of literature
on the use of drama to share health information across a
diverse range of health conditions (Rossiter et al. 2008).
Comparatively, little research has yet specifically focused
on the use of theatre to impact mental illness stigma;
this research project, to the best of our knowledge,
represents the first to address stigma specifically in
relation to BD. We demonstrated immediate impact on
stigma in health care providers and enduring qualita-
tive impact on stigma on individuals with BD through
a theatre-based intervention. The power of arts-based
approaches, which are consonant with the current
emphasis on narrative-based medicine, may lie in
their potential to reach and speak to an audience that
may not be responsive to conventional methods for
addressing stigma and may represent a yet-to-be fully
tapped mechanism for change.
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